In pancreatic ductal adenocarcinoma (PDAC), KRAS further increases the metabolic demands of tumor cells by enhancing glycolytic pathways, which exacerbates local lactate accumulation and contributes to immune suppression (143). This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.